Cannabidiol and SARS-CoV-2 Infection.

Area of Science:

• Molecular Biology
• Immunology
• Pharmacology

Background:

• SARS-CoV-2 infection triggers significant inflammatory responses, including the release of pro-inflammatory cytokines like IL-1beta, IL-6, IL-18, and TNF-alpha.
• The angiotensin-converting enzyme 2 (ACE2) is identified as a primary cell receptor for SARS-CoV-2 entry.
• The WNT/β-catenin pathway and PPARγ signaling exhibit complex interactions in SARS-CoV-2 pathophysiology.

Purpose of the Study:

• To investigate the potential of Cannabidiol (CBD) in mitigating the inflammatory effects of SARS-CoV-2.
• To explore the molecular mechanisms underlying CBD's interaction with SARS-CoV-2 infection pathways.
• To evaluate CBD's role as a potential therapeutic agent against SARS-CoV-2.

Main Methods:

• In vitro studies using Caco-2 cells to assess the impact of CBD on SARS-CoV-2 spike protein-induced inflammation.
• Analysis of cytokine levels (IL-1beta, IL-6, IL-18, TNF-alpha) in response to CBD treatment.
• Examination of CBD's interaction with ACE2, WNT/β-catenin pathway, and PPARγ.

Main Results:

• CBD demonstrated the ability to prevent the inflammatory response induced by SARS-CoV-2 spike protein in Caco-2 cells.
• CBD inhibited the release of key pro-inflammatory cytokines, including IL-1beta, IL-6, IL-18, and TNF-alpha.
• CBD's activity is linked to its interaction with PPARγ and potentially ACE2, suggesting a role in modulating the WNT/β-catenin pathway.

Conclusions:

• CBD exhibits anti-inflammatory and antiviral properties relevant to SARS-CoV-2 infection.
• CBD may counteract SARS-CoV-2-induced inflammation by interacting with ACE2 and modulating the interplay between the WNT/β-catenin pathway and PPARγ.
• Clinical trials are warranted to validate the therapeutic efficacy of CBD as a complementary treatment for COVID-19.